Abade Dos Santos Fábio A, Carvalho Carina L, Valente Pâmela C L G, Armés Henrique, Reemers Sylvia S, Peleteiro Maria C, Calonge Sanz Inés, Dalton Kevin P, Parra Francisco, Duarte Margarida D
Centre for Interdisciplinary Research in Animal Health (CIISA), Faculdade de Medicina Veterinária, Universidade de Lisboa, Avenida da Universidade Técnica, 1300-477 Lisbon, Portugal.
Instituto Nacional de Investigação Agrária e Veterinária (INIAV, I.P.), Av. da República, Quinta do Marquês, 2780-157 Oeiras, Portugal.
Vaccines (Basel). 2022 Feb 24;10(3):356. doi: 10.3390/vaccines10030356.
The recent emergence of a new myxoma virus capable of causing disease in the Iberian hare () has resulted in numerous outbreaks with high mortality leading to the reduction, or even the disappearance, of many local populations of this wild species in the Iberian Peninsula. Currently, the available vaccines that prevent myxomatosis in domestic rabbits caused by classic strains of myxoma virus have not been assessed for use in Iberian hares. The main objective of this study was to evaluate the efficacy of commercial rabbit vaccines in Iberian hares and wild rabbits against the natural recombinant myxoma virus (ha-MYXV), bearing in mind its application in specific scenarios where capture is possible, such as genetic reserves. The study used a limited number of animals (pilot study), 15 Iberian hares and 10 wild rabbits. Hares were vaccinated with Mixohipra-FSA vaccine (Hipra) and Mixohipra-H vaccine (Hipra) using two different doses, and rabbits were vaccinated with the Mixohipra-H vaccine or the Nobivac Myxo-RHD PLUS (MSD Animal Health) using the recommended doses for domestic rabbits. After the vaccination trials, the animals were challenged with a wild type strain of ha-MYXV. The results showed that no protection to ha-MYXV challenge was afforded when a commercial dose of Mixohipra-FSA or Mixohipra-H vaccine was used in hares. However, the application of a higher dose of Mixohipra-FSA vaccine may induce protection and could possibly be used to counteract the accelerated decrease of wild hare populations due to ha-MYXV emergence. The two commercial vaccines (Mixohipra-H and Nobivac Myxo-RHD PLUS) tested in wild rabbits were fully protective against ha-MYXV infection. This knowledge gives more insights into ha-MYXV management in hares and rabbits and emphasises the importance of developing a vaccine capable of protecting wild populations of Iberian hare and wild rabbit towards MYXV and ha-MYXV strains.
最近出现的一种能够在伊比利亚野兔()中引发疾病的新型黏液瘤病毒,已导致多次疫情爆发,死亡率很高,致使伊比利亚半岛许多当地野生该物种种群数量减少,甚至消失。目前,用于预防由经典黏液瘤病毒株引起的家兔黏液瘤病的现有疫苗,尚未评估其在伊比利亚野兔中的使用情况。本研究的主要目的是评估商业兔用疫苗对伊比利亚野兔和野兔抵抗天然重组黏液瘤病毒(ha-MYXV)的效果,同时考虑到其在特定可行捕捉场景(如基因保护区)中的应用。该研究使用了数量有限的动物(试点研究),15只伊比利亚野兔和10只野兔。野兔使用两种不同剂量接种Mixohipra-FSA疫苗(希普拉)和Mixohipra-H疫苗(希普拉),野兔使用针对家兔的推荐剂量接种Mixohipra-H疫苗或Nobivac Myxo-RHD PLUS(默沙东动物保健)。在疫苗接种试验后,用野生型ha-MYXV毒株对动物进行攻毒。结果表明,在野兔中使用商业剂量的Mixohipra-FSA或Mixohipra-H疫苗时,对ha-MYXV攻毒没有提供保护。然而,使用更高剂量的Mixohipra-FSA疫苗可能会诱导保护作用,并有可能用于应对由于ha-MYXV出现导致的野兔种群加速减少的情况。在野兔中测试的两种商业疫苗(Mixohipra-H和Nobivac Myxo-RHD PLUS)对ha-MYXV感染具有完全保护作用。这些知识为野兔和野兔中ha-MYXV的管理提供了更多见解,并强调了开发一种能够保护伊比利亚野兔和野兔野生种群免受MYXV和ha-MYXV毒株侵害的疫苗的重要性。